The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of CYP2D6 polymorphisms on adverse events in patients with breast cancer treated with tamoxifen: Insights from an early dose escalation trial in CYP2D6 poor metabolizers.
 
Isabel Blancas
Honoraria - AstraZeneca Spain; Bristol Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Grunenthal; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte; Veracyte
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Veracyte
Research Funding - Agendia (Inst); AstraZeneca Spain (Inst); Lilly; Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Other Relationship - Fundación San Juan de Dios; Medical Science Innovation Research (MEDSIR)
 
Eduardo Martínez-De Dueñas
Consulting or Advisory Role - Lilly; Novartis; Roche
 
Fernando Rodríguez-Serrano
No Relationships to Disclose